

NŪROSENE

CORPORATE PRESENTATION
MAY 20, 2021

A final prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in certain of the provinces and territories of Canada. A copy of the final prospectus, and any amendment, is required to be delivered with this document. This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the final prospectus, and any amendment, for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

General

Prospective investors should rely only on the information contained in the final prospectus of Nurosene Health Inc. (the “Company”) dated May 18, 2021 (the “prospectus”). The prospectus constitutes a public offering of securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. No securities regulatory authority has expressed an opinion about such securities and it is an offence to claim otherwise. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the prospectus. The Company and the Agents have not authorized anyone to provide prospective investors with additional or different information. Capitalized terms that are not defined in this presentation have the meanings ascribed to them in the prospectus.

For prospective purchasers outside Canada, neither the Company nor any of the Agents has done anything that would permit this offering or possession or distribution of the prospectus in any jurisdiction where action for that purpose is required, other than in Canada. Prospective investors are required to inform themselves about, and to observe any restrictions relating to, this offering and the possession or distribution of the prospectus.

There is no market through which the securities of the Company may be sold and investors may not be able to resell the securities purchased under the prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability of trading prices, the liquidity of these securities, and the extent of issuer regulation. Investment in the common shares of the Company is highly speculative and involves significant risk due to various factors, including the nature and early stage of the Company's business, limited operating history, lack of revenue to date and future revenue uncertainty and additional capital requirements. An investment in the securities of the Company should only be made by persons who can afford the total loss of their investment. Investors should consider the “Risk Factors” in the prospectus and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

The common shares of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any United States state securities laws and, subject to registration under the U.S. Securities Act and applicable United States state securities laws or certain exemptions therefrom, may not be offered, sold, transferred, delivered or otherwise disposed of, directly or indirectly, within the United States. None of the common shares of the Company have been approved or disapproved by the U.S. Securities and Exchange Commission, or any other securities commission or regulatory authority in the United States, nor have any of the foregoing authorities or any Canadian provincial or territorial securities regulator passed upon or endorsed the merits of the offering of the common shares of the Company nor have they approved this presentation or confirmed the accuracy or adequacy of the information contained in this presentation. Any representation to the contrary is a criminal offense.

Forward-Looking Information

Certain statements in this presentation constitute forward-looking statements within the meaning of applicable Canadian securities legislation (collectively herein referred to as “forward-looking statements”), which can often be identified by words such as “will”, “may”, “estimate”, “expect”, “plan”, “project”, “intend”, “anticipate” and other words or phrases such as “we are working to”, indicating that the statements are forward-looking. Specifically, this news release contains forward-looking statements relating to, but not limited to: ability to help users of the Company’s products; future growth of the mobile health and supplements industry; demand for the Company’s products; efficacy of the Company’s products and research efforts; product launch timeline and future products; use and success of digital marketing strategies to promote products; the Company’s ability to extract and use gathered or sourced data; the Company’s planned milestones and timing of same; and use of proceeds from the Offering. Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors, including, but not limited to, risk factors included in this presentation and the prospectus, that could cause the actual results, performance or achievements of the Company or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements.

Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals; whether the Company can successfully develop and commercialize products and future products and the efficacy thereof; the ability of our contract manufacturer to source raw materials; the ability of the Company to meet the milestones within the timelines provided; the ability to successfully execute and complete the Company’s business objectives; the success of plans to market, sell and distribute products and technologies; the successful deployment and execution of a data-driven digital marketing strategy; the identification and successful partnership with third party research institutions; the likelihood of success of any research and development; the successful development and execution of our predictive healthcare model in analyzing trends and patterns in user behavioural data to provide strategies to our user base and to guide further development of the Mobile Application; the effect of competition on the Company’s success; and reliance on the leadership team. These factors should be considered carefully and readers are cautioned not to place undue reliance on forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. Any graphs, tables or other information in this presentation demonstrating the historical performance of the Company or any other entity contained in this presentation are intended only to illustrate past performance of such entities and are not necessarily indicative of future results of the Company. No statement in this document is intended to be nor may be construed as a profit forecast.

An investment in the Company is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing their entire investment. Investors should consider the “Risk Factors” in the prospectus and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

The Company is in the early stage of development and has a limited operational history, making it difficult to accurately predict business operations. The Company has limited resources and may run out of capital prior to becoming profitable. The Company may fail and investors may lose their entire investment.

An investment in the Company may have tax consequences to the investor. The Company assumes no responsibility for the tax consequences of any investment. Investors should confer with their own tax advisors regarding an investment in the Company.

Notice to U.S. Investors: This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons,” as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

Risk Factors

An investment in the Company’s securities is speculative and is subject to a number of risks and uncertainties that should be considered by a prospective investor. Prospective investors should carefully consider the risk factors described under “Risk Factors” in the prospectus before purchasing securities of the Company.

WHO WE ARE



Daniel Gallucci
Chief Innovation Officer
Co-Founder

OUR GOAL IS TO HELP

Nurosene is a mental wellness company that currently offers two distinct solutions: a line of nutraceuticals, as well as a Mobile Application that helps users develop habits that are conducive to brain health through its curated content.

Our goal is to help users by offering actionable and adaptable strategies to improve daily mental health and overall brain performance.

NŪROSENE

THE TEAM



Ranj Bath

Chief Executive Officer
and Director

Mr. Bath is an inspirational leader with over 20 years of experience in various senior-level marketing and branding roles. Previously, as VP Corporate Strategy at Beats Music (the streaming service owned by the Beats Electronics division of Apple Inc.), he was instrumental in driving strategy, partnerships and revenue, working with the brand through a \$3Bn acquisition by Apple Inc.. Ranj is an avid investor and advisor across a number of health, wellness and technology companies, including being an early stage investor in companies such as Bulletproof 360 Inc. and ClassPass Inc. that has now reached over \$1Bn valuation.



Blake Sing

Chief Financial Officer

Mr. Sing has been the Chief Financial Officer and Corporate Secretary of the Company since February 1, 2021. Prior to his appointment as an officer of the Company, Mr. Sing provided consulting services for clients in regard to Financial Reporting, ERP implementation, reporting and control processes. Mr Sing was a Corporate Controller at WeedMD from June 2020 to December 2020, the VP Finance at Heritage Cannabis from December 2019 to March 2020, the Director of Finance for CannTrust Holdings Inc. from 2017 to 2019 and a manager at Ernst and Young LLP from 2013 to 2017. Mr. Sing received a Bachelor of Commerce from the University of Cape Town in 2010 and a CPA/CA Designation in 2017.



Daniel Gallucci

Chief Innovation Officer

Mr. Gallucci has been the Chief Innovation Officer of the Corporation since December 14, 2020. Mr. Gallucci was the founder and acted as Director of Rehabilitation and Performance for Flux Bionetworks from 2014 to present. Mr. Gallucci was the founder of DG2, a data driven rehabilitation company, from 2013 to present. He has a Bachelor in Exercise Science and a minor in Psychology from the University of Connecticut, Diplomat Osteopath Manual Practitioner (DOMP) from Sutherland Academy of Osteopathy. Additionally, he completed a clinical neuroscience program with specialities in Neurologic Performance, Traumatic Brain Injury, Vestibular Rehabilitation, Neurodevelopmental Rehabilitation and Neurochemistry from Carrick Institute of Graduate Studies.

NÜROSENE

DIRECTORS



Daniel Gallucci

Director

Mr. Gallucci has been the Chief Innovation Officer of the Corporation since December 14, 2020. Mr. Gallucci was the founder and acted as Director of Rehabilitation and Performance for Flux Bionetworks from 2014 to present. Mr. Gallucci was the founder of DG2, a data driven rehabilitation company, from 2013 to present. He has a Bachelor in Exercise Science and a minor in Psychology from the University of Connecticut, Diplomate Osteopath Manual Practitioner (DOMP) from Sutherland Academy of Osteopathy. Additionally, he completed a clinical neuroscience program with specialities in Neurologic Performance, Traumatic Brain Injury, Vestibular Rehabilitation, Neurodevelopmental Rehabilitation and Neurochemistry from Carrick Institute of Graduate Studies.



Mark Smithyes

Director

Mr. Smithyes was previously the President of Labtician Thea Inc. and a Country Head of the Pharmaceutical Business Unit at Alcon Inc., a Novartis company. He is currently the Chair of Life Sciences Ontario and was previously a Director at Medtech Canada and New Circles Community Services. He has an MBA from Northwestern University – Kellogg School of Management and was a graduate from Western University with a Bachelor of Arts.



Ranj Bath

Director

Mr. Bath is an inspirational leader with over 20 years of experience in various senior-level marketing and branding roles. Previously, as VP Corporate Strategy at Beats Music (the streaming service owned by the Beats Electronics division of Apple Inc.), he was instrumental in driving strategy, partnerships and revenue, working with the brand through a \$3Bn acquisition by Apple Inc.. Ranj is an avid investor and advisor across a number of health, wellness and technology companies, including being an early stage investor in companies such as Bulletproof 360 Inc. and ClassPass Inc. that has now reached over \$1Bn valuation.



Sheetal Jaitly

Director

Mr. Jaitly is the founder and CEO of TribalScale, a software design and development company. He has been working in the tech sector for over 15 years. Mr. Jaitly was also a Director at Xtreme Labs from August 2010 until August 2015. Additionally, he is a Board Member for the Ontario Association of Food Banks and participates as a mentor at the Founder Institute and the DMZ at Ryerson University.



Kirstine Stewart

Director

Kirstine Stewart is internationally recognised for her groundbreaking work and leadership at the intersection of media and technology. After establishing Twitter's first Canada office (pre IPO), she went on to lead Twitter's Media team across North America, including Entertainment, News and Sports. Prior, Kirstine was the head of the Canadian Broadcasting Corporation and all television, radio and online English services after a succession of global broadcasting executive roles at Hallmark Cards, Inc., Trio NewsWorld International and Alliance Atlantis Communications Inc. A supporter of tech entrepreneurship by establishing shows like Dragons' Den and formerly as an advisor with Ryerson's DMZ, Kirstine is a founding member of MaRS Coalition of Innovators Against Racism and currently sits on the CAMH Foundation Board. Kirstine is author of best-selling business book "Our Turn" published by Random House.




Andrew Parks

Director

Mr. Parks is the current CEO and Director of Fountain Asset Corporation. He was previously a Portfolio Manager and Research Analyst/Trader for Forge First Asset Management. He is a Chartered Financial Analyst from the CFA Institute. He graduated from Wilfred Laurier University with an Honours Bachelor of Business Administration.

OUR FOCUS

● **Nurosene has developed an ecosystem of actionable solutions that support building a healthier brain.**



OUR PRODUCTS

We have developed a Mobile Application that gives our users access to practical, habit forming activities and a line of proprietary nutraceutical supplements.

PREDICTIVE HEALTHCARE



We are working to leverage machine learning and artificial intelligence to collect trends and patterns to help better predict outcomes for our Mobile Application users. We plan to analyze trends and patterns in user behavioural data to generate insights to guide the development roadmap of our Mobile Application.

ALTERNATIVE THERAPIES & RESEARCH



We are dedicating efforts into creating partnerships focused on conducting studies to validate and refine our product offering, including our supplements and Mobile Application.

THE PROBLEM

- Mental, neurological and substance use disorders (MNS) are common, highly disabling, and associated with significant premature mortality.

The human, social and economic toll imposed by lack of attention to MNS across the world is considerable.¹

10%

It is estimated that at least 10% of the world's population is affected, and that 20% of children and adolescents suffer from some type of mental disorder.¹

264_M

People are affected by depression globally. More women are affected than men and depression is one of the main causes of disability worldwide.¹

76-85%

People with mental disorders receive no treatment.²

¹ <https://www.worldbank.org/en/topic/mental-health>

² <https://www.who.int/news-room/fact-sheets/detail/mental-disorders>



- **Mobile Health and Supplements are rapidly growing industries**

\$236_{BN}

The Mobile Health (mHealth) market size is projected to be worth \$236.0 Billion by 2026.¹

\$298_{BN}

The global dietary supplements market is expected to reach \$298.5 Billion by 2027.

Amid the COVID-19 crisis, the global market for dietary supplements was estimated at US\$170.4 Billion in 2020.²

¹ <https://www.grandviewresearch.com/press-release/global-mhealth-app-market>

² https://www.reportlinker.com/p05900383/Global-Dietary-Supplements-Industry.html?utm_source=GNW

OUR PRODUCTS

- Offering actionable and adaptable strategies to improve daily mental health and overall brain performance.

NŪROSENE



4X4 Model

The methodology behind our products is based on the Company's philosophy of the 4x4 model, which focuses on encouraging actionable strategies to affect 4 fundamental lifestyles (movement, cognitive training, nutrition, and recovery) with solutions aimed to affect 4 parts of the human body (spinal cord, cerebral cortex, brain stem, and peripheral nerves).


4X4 4 FUNDAMENTALS X 4 TARGETS

- Movement
- Brain
- Nutrition
- Recovery



SPINAL CORD

- Movement
- Brain
- Nutrition
- Recovery




PERIPHERAL NERVE




CEREBRAL CORTEX

- Movement
- Brain
- Nutrition
- Recovery



BRAIN STEM

- Movement
- Brain
- Nutrition
- Recovery




MOBILE APPLICATION

The Mobile Application was developed based on the principles of the Company's philosophy of the **4x4** model. The Mobile Application provides quick and efficient activities designed by our team, focused on each of the **4x4** model principles.

Examples of activities offered in the Mobile Application include: pursuit exercises, which require the user to follow an on-screen dot with their eyes; and gaze stabilization exercises, which require the user to focus on a dot while controlling their breathing. The activities are created with certain goals or outcomes in mind, or aim to provide certain benefits over time. For example, pursuits have been used by clinicians as a method of evaluating certain physical and behavioral disorders.

In addition to activities and supplement tracker, the Mobile Application also features blogs and a journal feature for the users.

NÜROSENE



We launched the Mobile Application on iOS and Android with no cost to the user in April 2021.

NUTRACEUTICAL PRODUCTS

The Company has developed two initial nutraceutical products, Nuro Drive and Nuro Restore, which will be available for purchase May 2021.



- Designed to help restore health by improving cellular structure and function and focusing on the interactions between cells in the body.
- The products were developed with an emphasis to help users feel their best and realize their potential.

NÜROSENE

- **The Mobile Application & Nutraceutical Supplements**

The Mobile Application features a built-in supplement tracker that can allow users to track their supplement intake through the app. The supplement tracker allows the user to go into the app, select the supplement they intend to take (Nuro Drive or Nuro Restore), enter a start date for their supplement cycle, and then answer a series of questions to establish a baseline of their overall health.

The user will be prompted every cycle, approximately every 4 weeks, for continuous interactive check-ins, as long as the user is using the product.

The user is not required to take both supplements to use this feature. Users are required to manually provide the Mobile Application information about their nutraceutical consumption.



NÜROSENE

Product Launch Timeline

Q2 2021

Q3 2021



NURO DRIVE

Designed and formulated, by our Chief Innovation Officer Daniel Gallucci, targeted at improving energy levels. The formulation consists of six (6) different B Vitamins alongside other ingredients, including K2-MK7, PQQ and COQ10. PQQ has been linked to potential health benefits such as improved energy utilization.¹



NURO RESTORE

Designed and formulated, by our Chief Innovation Officer Daniel Gallucci, targeted at improving sleep, reducing stress, and pain and inflammation. The formulation includes our proprietary blend: L-Cysteine, Glycine, L-theanine, 5 HTP and Gaba. Other ingredients include zinc, two forms of magnesium, and Vitamin B6). Consumption of magnesium supplements has been linked to relieving various neurological disorders, such as anxiety and depression.²



FUTURE PRODUCTS

The Company plans to introduce three (3) additional nutraceutical products in Q3 of the calendar year 2021. The Company will work with our contract manufacturer to source raw materials, and ensure quality assurance protocols are met.

NÜROSENE



¹ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804159/>

² <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024559/>

REACHING THE MARKET

• We plan to deploy data-driven digital marketing strategies to promote both our Mobile Application and our line of nutraceutical products, using a multi-layered and multi-channel approach, through:

- SOCIAL MEDIA
- SEARCH
- DISPLAY
- VIDEO
- MOBILE
- RE-MARKETING



Our product marketing program includes plans to engage in targeted advertising, influencer marketing and social media marketing.

Additionally, we intend to drive our marketing campaigns through a variety of channels including targeted promotions and business development efforts focused on professional and collegiate sports teams, college faculties, elite performance training centers, and personal health and fitness coaches.

NÜROSENE



ALTERNATIVE THERAPIES & RESEARCH



**Emphasize continued research,
innovation and advancements
in brain health.**

NÜROSENE

RESEARCH

- **Nurosene's business model emphasizes continued research, innovation and advancements in brain health.**

We are dedicating efforts into creating partnerships focused on conducting studies to validate and refine our product offering, including our supplements and Mobile Application.



NŪROSENE

N


N

- **PREDICTIVE HEALTHCARE**
Improved picture of an individual's mental health for today and for their future.

NÜROSENE

Better understand our users

The Company will utilize our user behaviour data gained from the users interaction with our Mobile Application to provide strategies and recommended solutions to our user base. As users continue to interact with the Mobile Application, the application will accumulate ongoing behavioural data from the user. We are enabling the ability to correlate passive and active data collected through application programming interfaces (APIs) to smartphones and wearables that will give us the utmost opportunity to find solutions and better understand the mental status of our users. Our in-house data scientist, utilizing machine learning, will determine patterning and provide an overall improved picture of an individual's mental health for today and for their future.



NÜROSENE


Help better predict outcomes

We will extract specific passive data points needed to help better predict outcomes as well as make suggestions for our users through the Mobile Application. Our Chief Innovation Officer will drive the initial data analysis outcomes in collaboration with our in-house data scientists' findings. With more users and data, the Company may seek partnerships with data analytics firms or with researchers to leverage our findings to improve developments in brain health, including through further development of the Mobile Application and/or nutraceuticals.

NŪROSENE



MILESTONES



NÜROSENE

¹ In the event the Company completes the Maximum Offering, the Company will allocate further funds to develop additional functionality and features for the Mobile Application.

COMPETITIVE LANDSCAPE

Uniquely Positioned

Technology Driven

Community Based

Researched Centered

Product Focused



NŪROSENE



The Company anticipates using the available funds for the following principal purposes:

| Principal Purposes | Estimated Expenditure (Minimum Offering) (\$) | Estimated Expenditure (Maximum Offering) (\$) |
|--|---|---|
| Estimated costs of the Offering ¹ | \$400,000 | \$400,000 |
| Mobile Application development | \$450,000 | \$1,940,000 |
| Nutraceutical product development | \$110,000 | \$110,000 |
| Manufacturing and Distribution | \$1,300,000 | \$1,600,000 |
| Sales and marketing | \$1,380,000 | \$1,380,000 |
| Research projects and partnerships | \$200,000 | \$1,200,000 |
| General and administrative | \$1,065,000 | \$1,065,000 |
| Payment of TribalScale | \$195,000 | \$195,000 |
| Available funds: | \$5,100,000 | \$7,890,000 |

1. Includes the agent's expenses, legal, audit, regulatory, listing and printing fees.

| | Outstanding after giving effect to the Minimum Offering | Outstanding after giving effect to the Maximum Offering | Outstanding after giving effect to exercise of full Agents' Over-Allotment Option ⁽¹⁾ (Unaudited) |
|--------------------------------|---|---|--|
| Common Shares | 28,530,412⁽²⁾⁽³⁾ | 31,863,745⁽²⁾⁽³⁾ | 33,197,078⁽²⁾⁽³⁾ |
| Incentive Stock Options | 1,635,000⁽⁴⁾ | 1,635,000⁽⁴⁾ | 1,635,000⁽⁴⁾ |
| Finder's Warrants | 185,788 | 185,788 | 185,788 |
| Agent's Options | 388,889 | 622,222 | 715,555 |
| Pro-Forma Fully Diluted | 30,740,089 | 34,306,755 | 35,733,421 |

(1) The Agents' Over-Allotment Option allows the Agents to sell up to an additional 1,333,333 Additional Shares at the Offering Price for additional gross proceeds of up to \$1,200,000. The Agents' Over-Allotment Option is exercisable at the discretion of the Agents, in whole or in part, at any time and from time for a period of 60 days following the Closing Date.

(2) Includes the Corporate Finance Fee Shares in the amount of 55,555 and assumes the Agents' Fee is paid in cash.

(3) Includes 493,827 Common Shares to be issued to the TribalScale on the Closing Date.

(4) Includes 300,000 Options to be granted to Ranjit Bath, 150,000 Options to be granted to Blake Sing, 220,000 Options to be granted to directors who are not also executive officers and 665,000 Options to be granted to consultants of the Company, all at the Offering Price on the Listing Date. See also "Options and Other Rights to Purchase Securities" in the prospectus.

NÜROSENE



NŪROSENE

Thank You

Investor Relations:
investors@nurosene.com